| CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall |
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. |
zacks.com |
2025-05-06 18:15:35 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript |
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrinology Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Roberto Vieira - President, Oncology Bill Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord David Amsellem - Piper Sandler Joon Lee - Truist Securities RK - H. C. Wainwright Operator Thank you for standing by. |
seekingalpha.com |
2025-05-06 00:34:47 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates |
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago. |
zacks.com |
2025-05-05 22:30:38 |
Czytaj oryginał (ang.) |
| CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. |
businesswire.com |
2025-04-28 20:05:00 |
Czytaj oryginał (ang.) |
| CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASC. |
businesswire.com |
2025-04-23 15:30:00 |
Czytaj oryginał (ang.) |
| Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss |
Despite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potential patient population has expanded significantly from 10,000 to over 1 million in the past year, and has promising drugs in the pipeline, making it a strong acquisition target. The company announced positive trial results for an ovarian cancer medication, opening an entirely new revenue stream. |
seekingalpha.com |
2025-04-22 21:23:40 |
Czytaj oryginał (ang.) |
| Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association. The publication,. |
businesswire.com |
2025-04-21 12:00:00 |
Czytaj oryginał (ang.) |
| It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder |
Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resistant ovarian cancer and potential FDA approval for hypercortisolism could significantly boost Corcept's market presence and revenue. Corcept's expanding pipeline includes promising treatments for prostate cancer, ALS, MASH, and resistant hypertension, diversifying its product portfolio and reducing investor risk. |
seekingalpha.com |
2025-04-15 20:00:31 |
Czytaj oryginał (ang.) |
| 3 Biopharmaceutical Stocks Bucking the Sell-Off |
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market. |
marketbeat.com |
2025-04-10 11:02:06 |
Czytaj oryginał (ang.) |
| Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer. BELLA is a. |
businesswire.com |
2025-04-07 12:00:00 |
Czytaj oryginał (ang.) |
| Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-02 15:00:53 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release |
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data. |
seekingalpha.com |
2025-04-01 17:43:09 |
Czytaj oryginał (ang.) |
| CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal |
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint. |
zacks.com |
2025-04-01 15:51:04 |
Czytaj oryginał (ang.) |
| Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? |
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-01 15:30:40 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Corcept (CORT) Should Keep going |
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2025-04-01 13:50:51 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company |
Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal, showing promise for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial demonstrated a median progression-free survival of 6.5 months and a significant overall survival gain of 4.5 months with relacorilant. Relacorilant's lack of new safety issues and potential for wide use, combined with promising survival data, suggest strong market potential and likely FDA approval by 2026. |
seekingalpha.com |
2025-04-01 11:15:21 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast |
Corcept Therapeutics Incorporated CORT announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR). |
benzinga.com |
2025-03-31 19:01:38 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results |
Corcept Therapeutics (NASDAQ:CORT) shares surged more than 85% after the company announced positive results from its Phase 3 ROSELLA trial, evaluating relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer, that will support regulatory applications in the US and Europe. The trial met its primary endpoint, demonstrating a 30% reduction in the risk of disease progression compared to nab-paclitaxel alone. |
proactiveinvestors.com |
2025-03-31 16:44:11 |
Czytaj oryginał (ang.) |
| Corcept's ovarian cancer combination drug meets main goal in late-stage study |
Corcept Therapeutics said on Monday its experimental ovarian cancer drug in combination with chemotherapy met the main goal of a late-stage trial. |
reuters.com |
2025-03-31 12:18:15 |
Czytaj oryginał (ang.) |
| Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company's pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progres. |
businesswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| CORT's Q4 Earnings and Revenues Fall Short of Estimates |
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales. |
zacks.com |
2025-02-27 13:31:13 |
Czytaj oryginał (ang.) |
| Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-27 12:50:35 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT)Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. |
accessnewswire.com |
2025-02-27 11:15:00 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript |
Corcept Therapeutics, Inc. (NASDAQ:CORT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Joe Belanoff - Co-Founder, President, CEO & Director Bill Guyer - Chief Development Officer Sean Maduck - President, Endocrinology Conference Call Participants David Amsellem - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Asim Rana - Truist Operator Thank you for standing by, and welcome to Corcept Therapeutics conference call. |
seekingalpha.com |
2025-02-26 23:53:04 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates |
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.28 per share a year ago. |
zacks.com |
2025-02-26 21:05:28 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2024. Financial Results “Once again, we had a record number of new Korlym® prescribers and a record number of patients receivin. |
businesswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who purchased Corcept securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CORT. |
accessnewswire.com |
2025-02-25 12:30:00 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate update on February 26, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in numb. |
businesswire.com |
2025-02-12 18:05:00 |
Czytaj oryginał (ang.) |
| Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock? |
Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-01-31 11:40:30 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era |
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio. |
zacks.com |
2025-01-31 11:05:28 |
Czytaj oryginał (ang.) |
| All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy |
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2025-01-29 15:05:33 |
Czytaj oryginał (ang.) |
| Big Money Keeps Buying Corcept |
Corcept Therapeutics Incorporated (CORT) shares rise on treatment advances, Big Money buys. |
fxempire.com |
2025-01-29 09:37:04 |
Czytaj oryginał (ang.) |
| Buy These 5 Stocks With Recent Price Strength Amid a Volatile January |
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are OPFI, CORT, DXPE, PPTA, GHM. |
zacks.com |
2025-01-29 09:36:11 |
Czytaj oryginał (ang.) |
| Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2025-01-24 15:46:34 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm |
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Inc. (NASDAQ: CORT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-24 13:00:00 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue? |
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-01-24 12:16:17 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics Generating Strong Revenue And Profit Growth |
Corcept's sole drug, Korlym, treats Cushing Syndrome, a more prevalent condition than previously known, driving strong revenue and profit growth. A new market for Corcept's medications, diabetics, is poised to take the company to the next level. Long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant, which could expand market reach beyond Korlym. |
seekingalpha.com |
2025-01-22 16:03:59 |
Czytaj oryginał (ang.) |
| Medical Stock Soars To Highs As Cortisol Screening Grows |
Corcept Therapeutics makes drugs that modulate cortisol. The post Medical Stock Soars To Highs As Cortisol Screening Grows appeared first on Investor's Business Daily. |
investors.com |
2025-01-22 13:35:46 |
Czytaj oryginał (ang.) |
| Corcept Submits Application for Another Cushing's Syndrome Drug |
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism. |
zacks.com |
2024-12-31 16:56:07 |
Czytaj oryginał (ang.) |
| Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolis. |
businesswire.com |
2024-12-30 19:15:00 |
Czytaj oryginał (ang.) |
| Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism (Cushing's syn. |
businesswire.com |
2024-12-12 18:05:00 |
Czytaj oryginał (ang.) |
| CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study |
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal. |
zacks.com |
2024-12-12 13:26:08 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics' ALS drug fails in mid-stage trial |
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. |
reuters.com |
2024-12-11 19:27:31 |
Czytaj oryginał (ang.) |
| Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial evaluating two doses (150 mg and 300 mg) of its proprietary selective cortisol modulator. |
businesswire.com |
2024-12-11 18:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-11 12:50:23 |
Czytaj oryginał (ang.) |
| Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why |
Corcept (CORT) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2024-12-09 15:46:21 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High? |
The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-12-06 12:55:29 |
Czytaj oryginał (ang.) |
| What Makes Corcept (CORT) a Good Fit for 'Trend Investing' |
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-12-06 11:51:09 |
Czytaj oryginał (ang.) |
| Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? |
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-29 14:37:44 |
Czytaj oryginał (ang.) |
| Corcept Therapeutics: A Most Promising And Compelling Biotech |
Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's robust financials, strong profitability, and near-monopolistic position in a niche market underscore its investment potential despite legal risks and reliance on a single product. The company's innovative pipeline, especially Relacorilant, could significantly expand its market reach and diversify revenue streams, driving strong future growth. |
seekingalpha.com |
2024-11-27 10:00:00 |
Czytaj oryginał (ang.) |
| Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-25 12:56:35 |
Czytaj oryginał (ang.) |
| Corcept Shares Rise More Than 60% in Three Months: Here's Why |
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly. |
zacks.com |
2024-11-22 14:36:16 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love Corcept (CORT) |
Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-11-21 15:46:09 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-20 12:55:26 |
Czytaj oryginał (ang.) |
| Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable |
Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
zacks.com |
2024-11-20 11:50:31 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance |
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article. |
zacks.com |
2024-11-11 10:51:11 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Trump Gets Re-Elected |
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio. |
zacks.com |
2024-11-08 10:21:31 |
Czytaj oryginał (ang.) |
| 5 Stocks With Recent Price Strength to Tap Wall Street Rally |
Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT. |
zacks.com |
2024-11-08 10:10:35 |
Czytaj oryginał (ang.) |